Use of selective serotonin-reuptake inhibitors during early pregnancy and risk of congenital malformations: updated analysis
Jette B Kornum1, Rikke B Nielsen1, Lars Pedersen1, Preben B Mortensen2, Mette Nørgaard1
1Department of Clinical Epidemiology, Aarhus University Hospital, Denmark; 2National Center for Registry-based Research, University of Aarhus, Aarhus, Denmark
Background: Data on the safety of selective serotonin-reuptake inhibitors (SSRIs) in pregnancy are inconsistent. We examined associations between SSRI use during early pregnancy and risk of congenital malformations in infants.
Methods: Set in Northern Denmark, our population-based prevalence study included 216,042 women who had a live birth after the 20th week of gestation. We compared the prevalence of malformation in infants born to women who redeemed at least one SSRI prescription during early pregnancy with the prevalence in infants born to women who redeemed no SSRI prescriptions during their pregnancies. Drug use data were extracted from prescription databases, while data on congenital malformations were obtained from the National Registry of Patients.
Results: The 2,062 women with SSRI prescriptions during early pregnancy gave birth to 105 (5.1%) infants with malformations, while the 213,712 women with no SSRI prescriptions gave birth to 7,449 (3.5%) infants with malformations. SSRI use was associated with an increased risk of malformations overall (odds ratio [OR] = 1.3; 95% confidence interval (CI): 1.1–1.6) and cardiac malformations (OR = 1.7; 95% CI: 1.1–2.5). For specific SSRIs, we found an increased risk for septal defects associated with sertraline.
Conclusions: We found little overall association between use of SSRIs during pregnancy and congenital malformations, but our findings suggest an association between maternal SSRI use in early pregnancy and cardiac malformations which could be causal.
Keywords: antidepressants, drug safety, pregnancy, congenital malformations, epidemiology
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.Download Article [PDF]
Readers of this article also read:
Effects of a pain self-management intervention combining written and video elements on health-related quality of life among people with different levels of education
Stalker C, Elander J
Published Date: 20 August 2015
Response to “Oral health in the elderly patient and its impact on general well-being: a nonsystematic review” paper
Muc-Wierzgoń M, Kokot T, Nowakowska-Zajdel E, Błażelonis A, Fatyga E
Published Date: 2 May 2015
The severe complication of Stevens–Johnson syndrome induced by long-term clozapine treatment in a male schizophrenia patient: a case report
Wu MK, Chung WL, Wu CK, Tseng PT
Published Date: 9 April 2015
Momtaz YA, Haron SA, Hamid TA, Ibrahim R, Masud J
Published Date: 17 December 2014
Balsamo M, Giampaglia G, Saggino A
Published Date: 28 January 2014
Fadoo Z, Merchant Q, Rehman KA
Published Date: 23 July 2013
Querques G, Avellis FO, Querques L, Bandello F, Souied EH
Published Date: 18 May 2011
Published Date: 9 February 2011
The use of PEGylated liposomes in the development of drug delivery applications for the treatment of hemophilia
Rivka Yatuv, Micah Robinson, Inbal Dayan-Tarshish, et al
Published Date: 6 August 2010
Pitipol Choopong, Nattaporn Tesavibul, Nattawut Rodanant
Published Date: 14 July 2010